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In non-cancerous breast cell lines HB2 andMCF10A the TP53 gene is localized inside a relatively small ~ 50 kb
loop domain delimited by two S/MARs.Aim. To analyze the chromatin markers H4Ac and H3K9me3 of these two
S/MARs and of the TP53 gene P1 promoter in different breast cells lines. Methods. We used chromatin
immunoprecipitation (ChIP) to characterize the chromatin status of these S/MARs elements in breast non-can-
cerous cell lines HB2 and MCF10A and cancerous MCF-7, MDA-MB-231, BT-474 and T47D cell lines, by
chromatin enrichment of H4Ac and H3K9me3 epigenetic markers, hallmarks of open and closed chromatin,
respectively. Results. We found that these chromatin epigenetic markers are differentially distributed in S/MARs
for all analyzed breast cell lines. Conclusions. We found no correlation between S/MARs and chromatin epige-
netic status, suggesting that nuclear matrix fixation and chromatin status can be independent. High enrichment
of H3K9me3 in the TP53 gene P1 promoter region in MCF-7, could explain lower levels of the TP53 expression,
described earlier by our group.
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Introduction. DNA in eukaryotic nucleus is organized
in nucleosomes consisting of ~ 147 bp of DNAwrapped
around an octamer of four core histone proteins (H2A,
H2B, H3 and H4). The N-terminal tail of histones is a
subject to several types of post-translational modifica-
tions, the two most important of which are acetylation
and methylation of some amino acids, usually lysine.
These histone modifications can affect the chromatin as-
sembly making it permissible for proteins to modulate
cellular processes such as transcription, repair, replica-
tion and genome stability [1–4]. Histone acetylation
and methylation are catalyzed by histone acetyltransfe-
rases (HATs) and histone methyltransferases (HMTs),
respectively. Histone H4 acetylation (H4Ac) is a hall-
mark of open chromatin or euchromatin and may be a
sign of gene activation [5–7]. It is generally decreased
in breast cancer cell lines and tissues [8, 9]. In contrast,
histone H3 lysine 9 trimethylation (H3K9me3) is a hall-
mark of closed chromatin or constitutive heterochro-
matin and may denote gene repression [10, 11]. Chro-
matin is further organized in DNA loop domains delimi-
ted by the border elements that include nuclear Scaf-
fold/Matrix Attachment Regions (S/MARs), which could
be 20 to 200 kb long [12, 13]. The S/MARs are respon-
sible for DNA attachment to the nuclear matrix (NM)
and are linked to DNA replication and transcription.
They may include Topoisomerase II binding sites [14,
15] as well as other sequence motifs. Furthermore, NM
is enriched in several transcription factors, which have
been suggested to be MAR binding proteins (MARBPs)
[16–18].
Several factors potentially affect the association of
DNA with the NM, including the DNA sequence itself
and its epigenetic state [19–22]. Scaffold Attachment
Regions (SARs) can be enriched in H4Ac [23]. The at-
tachment of human S/MARs to the nuclear matrix de-
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pends on a high DNA methylation level and the absen-
ce of H3K9ac within S/MAR [24]. Interestingly, some
histone modification enzymes such as HATs are asso-
ciated with NM [25]. Additionally, the loops can be ac-
tive or inactive due to the MARs chromatin enrich-
ment in H4Ac or H3K9me3, respectively [26].
However, as nuclear matrix remains a controversial
concept [13] and the data on the interplay between
MARs and histone epigenetic chromatin status are still
absent, we decided to test whether the association of
S/MARs with the nuclear matrix in breast cancer cell
lines corresponds to specific chromatin modifications.
We have previously mapped S/MARs in the 167 kb
locus of the tumor suppressor gene TP53 in cancerous
breast cell lines, MDA-MB-231, BT-474, T47D,MCF-
7, and non-cancerous breast cell lines, MCF10A and
HB2, using DNA arrays [27]. We found that the loop
domain organization in these cell lines was quite va-
riable. MAR2 and MAR3 were detected in non-can-
cerous cells HB2 and MCF10A, and MAR3 was detec-
ted in cancerous cells BT-474 and T47D. Interestingly,
theseMARswere symmetrically disposed in relation to
the TP53 gene P1 promoter, probably constituting the
borders of a chromatin loop. Now, in an attempt to
check the chromatin accessibility of these two S/MARs
and the TP53 gene P1 promoter region we evaluated
the chromatin enrichment levels of the histone epi-
genetic markers H4Ac and H3K9me3 (linked to open
and closed chromatin, respectively), by the chromatin
immunoprecipitation (ChIP) assay, in the same breast
cells lines. We found no correlation between the chro-
matin enrichment of histone epigenetic marks and nuc-
lear matrix attachment regions.We believe that our res-
ults will help to get a better understanding on the TP53
chromatin domain organization and transcriptional
control.
Materials and methods. Cell lines. All cell lines
were obtained fromDavid Cappellen and Nancy Hynes
(FriedrichMiescher Institute for BioMedical Research,
Novartis Research Foundation, Switzerland). The hu-
man mammary carcinoma cell lines MDA-MB-231 and
T47D were cultured in DMEM medium supplemented
with 10 % bovine serum, 0.5 % penicillin/streptomycin
and 1% glutamine. The human mammary carcinoma cell
lines MCF-7 and BT-474 were cultured in RPMI medi-
um supplemented with 10 % bovine serum, 0.5 % peni-
cillin/streptomycin and 1% glutamine. The control non-
cancerous epithelial cell lines MCF10A and HB2 were
cultured in DMEM medium supplemented with 10 %
horse serum, 0.5 g/ml hydrocortisone, 10 g/ml insu-
lin, 0.5 % penicillin/streptomycin and 1 % glutamine.
ChIP assay. 25 10
6 cells were cross-linked with 1%
formaldehyde for 10 min in a rocking platform at room
temperature. Cross-linking reaction was stopped with
0.125MGlycine diluted in 1PBS. The cells were wa-
shed with ice-cold 1X PBS and resuspended in 1 ml Ly-
sis/Sonication cold buffer (1 % SDS, 10 mMEDTA and
50 mM Tris-HCl, pH 7.5) with fresh 0.5 mM PMSF
and 1PIC (Protease Inhibitor Cocktail) and incubated
for 30 min on ice. The lysates were homogenized with
10 strokes, centrifuged at 750g for 5 min at 4 °C and the
supernatant was discarded. The pellet was resuspended
in 350 l of Lysis/Sonication cold buffer with freshly
added 1 mM PMSF and 1  PIC, sonicated on ice and
centrifuged for 10 min with 2000g at 4 °C. The superna-
tant contains extracted chromatin. The immunoprecipi-
tation was carried out overnight at 4 °C with constant
agitation in an immunoprecipitation buffer (5 mMTris-
HCl, pH 8.0, 15 mMNaCl, 1 mMEDTA and 0.1 %NP
40) with 20g of chromatin, 750g of Protein G dyna-
beads #100.03D («Invitrogen®», USA), 4 µg of antibo-
dies H4 pan-acetyl (#39243, «Active Motif®»), trime-
thyl H3K9 (#05-1242, «Millipore®»), normal rabbit
IgG (#PP64B, «Millipore®»; control) and 1 PIC. All
the immunoprecipitationsweremade at 1:4 dilutions. The
magnetic beads were washed 6 times with the immuno-
precipitation buffer and the chromatin was eluted with
the Lysis/sonication buffer for 15min at room temperatu-
re with constant agitation.
The chromatin was eluted frommagnetic beads and
reversed cross-linked by 5.25dilution with 0.2380 M
NaCl, denatured at 95 °C for 15 min, after 1l of RNA-
se A (10g/l) was added and incubated at 37°C for 15
min and 1 l of proteinase K (10 g/l) was added and
incubated at 67 °C for 15 min. DNAwas cleaned-up by
the standard Phenol-Chloroformmethod and submitted
to qPCR. qPCR, was carried out using the standard
Syber-Green method with the Mastermix («Roche®»,
France).
All fold enrichment values of H4Ac and H3K9me3
are relative to the fold enrichment values of the -actin
gene region or the alpha-satellite region, respectively.
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All primers, synthesized by SIGMA®, are listed in 5'–3'
and F – forward, R – reverse:
MAR2: F – CTGGCCGGAAATGTTTTCTA, R –
GTGCCAGGAGCTGTTCTAGG;
MAR3: F – GTCTGGAGCTATTTGAAAATG, R –
TGTCTTCCTGTGCCTGTAGTC;
TP53P1: F – GCGTGTCACCGTCGTGGAAAG,
R – GGAGCCTCGCAGGGGTTGATG;
-actin gene region: F – GACGTAGCACAGCT
TCTCCT, R – GGGACCTGACTGACTACCTCAT;
Alpha-Satellite (#CS207313, Millipore®) F – CTG
CACTACCTGAAGAGGAC, R – GATGGTTCAAC
ACTCTTACA.
All chromatin extraction, immunoprecipitation and
qPCR were done in triplicate and the error bars corres-
ponded to the S.E.M. of three different experiments.
Statistic analysis. All statistic data and graphics we-
re performed by the GraphPad version 6.0 using unpai-
red t-test analyses with Welch’s correction and 95 %
confidence interval.
Results and discussion. Association of S/MARs in
breast cells is independent of H4Ac and H3K9me3 en-
richment levels. Scaffold/Matrix Attachment Regions
(S/MARs) have been described as cis-acting factors in-
volved in DNA replication, transcription regulation and
chromatin organization. Possibly they take part in the
coordination of these cellular processes [28–30]. The
tumor suppressor gene TP53 is one of the most studied
genes implicated in cancer and, despite a huge know-
ledge on its post-translational regulation [31, 32], its
transcription control and genomic domain are not very
well established [33]. In a previous work we described
MARs in a genomic region of 167 kb containing the
TP53 and neighboring genes, using different cell lines
[27]. Here we concentrated our study on twoMARs, na-
mely MAR2 and MAR3.
Interestingly, the association ofMAR2with the nuc-
lear matrix was detected only in two analyzed non-
cancerous cell lines HB2 andMCF10Awhere the TP53
gene is organized into a ~ 50 kb loop domain flanked
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Fig. 1. Chromatin state of MARs in breast cell lines in TP53 domain: A – TP53 genomic region organization based on NCBI database: NT_
010718.16:7.1M-7.2M (94 kb+), covering the 167 kb genomic domain at the 17p13.1 chromosomal region (genes are represented by horizontal
bars and arrows indicate the analyzed MARs – black; positions of MAR2 and MAR3 are indicated by black arrows, relatively to position 0, which
corresponds to the major transcription start site (P1) of TP53 (TP53P1, indicated by a gray arrow); in the HB2 andMCF10A cell lines, MARs 2 and 3
delimitate a 50 kb loop encompassing the TP53, WRAP53 and EFNB3 genes); B – ChIP assay of MAR2 and MAR3, indicating the enrichment of
euchromatin marker H4Ac (black column)(relative to beta-actin gene region) and heterochromatin marker H3K9me3 (grey column) (relative do
alpha-satellite gene region); the cell lines utilized to describe MAR2 or MAR3 are underlined. Error bars correspond to +/–S.E.M. from 3 different
experiments; *p < < 0.05; **p < < 0.005; ***p < 0.0001
by two S/MARs (Fig. 1, A). This organization is pertur-
bed in cancerous cell lines MDA-MB-231, BT-474,
T47D andMCF-7 [27]. Chromatin is composed of DNA
and proteins, mostly histones, which are involved in ge-
nomic DNA organization in the nuclei. Histone altera-
tions in N-terminal tail by acetylation, methylation or
ubiquitylation may produce different levels of DNA
compaction, leading to an open chromatin or euchroma-
tin, permissive to the protein factors access, or leading
to close chromatin or heterochromatin, repressive for the
association of transcription factors [34–37]. These his-
tone alterations may be tracked using a ChIP assay, and
give an idea of the chromatin ambiance through the epi-
genetic profile at a genomic site, in normal and cance-
rous cells [38, 39]. In order to gain insight of the me-
chanisms governing the attachment of these two S/
MARs, MAR2 andMAR3, in normal and breast cancer
cell lines and to determine the chromatin state at S/
MARs, we performed the ChIP assays to detect the en-
richment of both H4Ac and H3K9 me3 euchromatin
and heterochromatin markers, respectively, in two non-
cancerous cell lines: HB2 and MCF10A, and in four
cancerous cell lines: MCF-7, T47D, BT-474 andMDA-
MB-231 (Fig. 1, B). As presented in Fig. 1, B, we could
not identify a specific pattern of the epigenetic histone
markers enrichment in non-cancerous and cancerous
cells, despite certain differences between histone mar
kers when MAR3 are present in cancerous cells, BT-
474 and T47D.
Moreover, the histone enrichment levels were quite
different among cell lines, suggesting that neither
H4Ac nor H3K9me3, chromatin enrichments, are lin-
ked to S/MARs. Indeed, a link between the association
of these regions to the NM and active histone marks re-
mains controversial [13, 24, 40]. These results, suggest
that nuclear matrix fixation and chromatin epigenetic
status can be independent.
Chromatin status of TP53 gene P1 promoter can be
linked to TP53 transcription in MCF-7 cells. We have
simultaneously performed ChIP assays in the TP53 gene
P1 promoter region (TP53P1) to detect chromatin chan-
ges associated with the TP53 transcriptional status (Fig.
2). Indeed, in the cell lines, TP53 is less expressed in can-
cerous cells, relative to HB2, as follows: ~ 2.5X inMCF-
7 and T47D, ~ 1.66X in MDA-MB-231 and ~ 1.11X in
BT-474 [27]. Interestingly, a higher enrichment of hetero-
chromatin marker H3K9me3 in TP53P1 in MCF-7, as
shown in Fig. 2, corroborates the lowest level of the TP53
gene expression observed in this cell line. Also, a high-
er enrichment of H4Ac in the non-cancerous cell lines,
MCF10A and HB2, corroborates higher levels of TP53
described in HB2, in our earlier report [27].These results
together suggest that chromatin status of the P1 TP53
promoter, can regulate the TP53 expression in some
breast cell lines.
Conclusions. Our results show no correlation bet-
ween S/MARs and H4 acetylation/H3K9 trimethyla-
tion, suggesting that nuclear matrix fixation and these
specific chromatin modifications are possibly indepen-
dent events during breast cancer progression. Also, chro-
matin status of the P1 TP53 promoter can regulate TP53
expression in the MCF-7 cell line.
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Fig. 2. Chromatin state of TP53 P1 Promoter re-
gion. ChIP assay of the TP53 P1 promoter regi-
on, indicating the enrichment of euchromatin
marker H4Ac (black column) (relative to beta-
actin gene region) and heterochromatin marker
H3K9me3 (grey column) (relative do alpha-sa-
tellite gene region). Error bars cor respond to +/–
S.E.M. from 3 different experiments; *p < 0.05;
****p < 0.00001
Çáàãà÷åííÿ õðîìàòèíîâèìè ìàðêåðàìè H4Ac ³ H3K9me3 äîìåíó
ãåíà TP53 ó êë³òèííèõ ë³í³ÿõ ìîëî÷íî¿ çàëîçè
Ã. Äæ. Ð. Ñàíòîñ, A. C. Ñ. Õîåñ, Ê. Â. äå Ìîóðà Ãàëëî
Ðåçþìå
Ó íåîíêîãåííèõ êë³òèííèõ ë³í³ÿõ HB2 ³ MCF10A ãåí TP53 ðîçòàøî-
âàíèé âñåðåäèí³ â³äíîñíî íåâåëèêî¿ ïåòë³ õðîìàòèíó (~ 50 òèñ.
ïàð íóêëåîòèä³â), îáìåæåíî¿ äâîìà ä³ëÿíêàìè ïðèêð³ïëåííÿ äî
ÿäåðíîãî ìàòðèêñó (ÄÏÌ).Ìåòà. Ïðîàíàë³çóâàòè õðîìàòèíîâ³
ìàðêåðè H4Ac ³ H3K9me3 ó çàçíà÷åíèõ ÄÏÌ ³ P1 ïðîìîòîð³ ãåíà
TP53 â ð³çíèõ êë³òèííèõ ë³í³ÿõ ìîëî÷íî¿ çàëîçè. Ìåòîäè. ²ìóíî-
ïðåöèï³òàö³þ õðîìàòèíó çà äîïîìîãîþ àíòèò³ë ïðîòè ìàðêåð³â
àêòèâíîãî õðîìàòèíó H4Ac ³ ãåòåðîõðîìàòèíó H3K9me3 âèêîðè-
ñòàíî äëÿ õàðàêòåðèñòèêè ñòàíó õðîìàòèíó åëåìåíò³â ÄÏÌ ó
íåîíêîãåííèõ êë³òèííèõ ë³í³ÿõ HB2 ³ MCF10A òà çëîÿê³ñíèõ êë³-
òèííèõ ë³í³ÿõ MCF-7, MDA-MB-231, ÁÒ-474 ³ T47D. Ðåçóëüòàòè.
Çàçíà÷åí³ åï³ãåíåòè÷í³ ìàðêåðè íåð³âíîì³ðíî ðîçïîä³ëåí³ â äîñë³ä-
æóâàíèõ ÄÏÌ äëÿ âñ³õ ïðîàíàë³çîâàíèõ ë³í³é êë³òèí ìîëî÷íî¿ çà-
ëîçè. Âèñíîâêè. Íå çíàéäåíî êîðåëÿö³¿ â åï³ãåíåòè÷íîìó ñòàòóñ³
ÄÏÌ ³ õðîìàòèíó. Öå äîçâîëÿº ïðèïóñòèòè, ùî ô³êñàö³ÿ ó ÿäåðíî-
ìó ìàòðèêñ³ ³ ñòàòóñ õðîìàòèíó ìîæóòü áóòè íåçàëåæíèìè.
Ñóòòºâå çáàãà÷åííÿ H3K9me3 P1 ïðîìîòîðíî¿ îáëàñò³ ãåíà TP53
êë³òèííî¿ ë³í³¿ MCF-7 ìîæå áóòè ïðè÷èíîþ íèæ÷èõ ð³âí³â åêñïðå-
ñ³¿ TP53, îïèñàíèõ ðàí³øå íàøîþ ãðóïîþ.
Êëþ÷îâ³ ñëîâà: TP53, õðîìàòèí, ïåòëåâèé äîìåí, ÌÀÐ, ðàê ìî-
ëî÷íî¿ çàëîçè, åï³ãåíåòè÷í³ ìîäèô³êàö³¿ ã³ñòîí³â, ÷èï àíàë³çó.
Îáîãàùåíèå õðîìàòèíîâûìè ìàðêåðàìè H4Ac è H3K9me3
äîìåíà ãåíà TP53 â êëåòî÷íûõ ëèíèÿõ ìîëî÷íîé æåëåçû
Ãþ Äæ. Ð. Ñàíòîñ, A. C. Ñ. Ãîåñ, Ê. Â. äå Ìîóðà Ãàëëî
Ðåçþìå
Â íåîíêîãåííûõ êëåòî÷íûõ ëèíèÿõ HB2 è MCF10A ãåí TP53 ðàñïî-
ëîæåí âíóòðè îòíîñèòåëüíî íåáîëüøîé ïåòëè õðîìàòèíà (~ 50
òûñ. ïàð íóêëåîòèäîâ), îãðàíè÷åííîé äâóìÿ ó÷àñòêàìè ïðèêðåï-
ëåíèÿ ê ÿäåðíîìó ìàòðèêñó (ÓÏÌ).Öåëü. Ïðîàíàëèçèðîâàòü õðî-
ìàòèíîâûå ìàðêåðû H4Ac è H3K9me3 â óêàçàííûõ ÓÏÌ è P1
ïðîìîòîðå ãåíà TP53 â ðàçëè÷íûõ êëåòî÷íûõ ëèíèÿõ êëåòîê ìî-
ëî÷íîéæåëåçû.Ìåòîäû. Èììóíîïðåöèïèòàöèþ õðîìàòèíà ñ ïî-
ìîùüþ àíòèòåë ïðîòèâ ìàðêåðîâ àêòèâíîãî õðîìàòèíà H4Ac è
ãåòåðîõðîìàòèíà H3K9me3 èñïîëüçîâàëè äëÿ õàðàêòåðèñòèêè
ñîñòîÿíèÿ õðîìàòèíà ýëåìåíòîâ ÓÏÌ â íåîíêîãåííûõ êëåòî÷-
íûõ ëèíèÿõ HB2 è MCF10A è çëîêà÷åñòâåííûõ êëåòî÷íûõ ëèíèÿõ
MCF-7, MDA-MB-231, ÁÒ-474 è T47D. Ðåçóëüòàòû. Óêàçàííûå
ýïèãåíåòè÷åñêèå ìàðêåðû íåðàâíîìåðíî ðàñïðåäåëåíû â èññëåäî-
âàííûõ ÓÏÌ äëÿ âñåõ àíàëèçèðóåìûõ ëèíèé êëåòîê ìîëî÷íîéæå-
ëåçû. Âûâîäû. Íå âûÿâëåíà êîððåëÿöèÿ â ýïèãåíåòè÷åñêîì ñòà-
òóñå ÓÏÌ è õðîìàòèíà. Ýòî ïîçâîëÿåò ïðåäïîëîæèòü, ÷òî ôèê-
ñàöèÿ â ÿäåðíîì ìàòðèêñå è ñòàòóñ õðîìàòèíà ìîãóò áûòü íåçà-
âèñèìûìè. Ñóùåñòâåííîå îáîãàùåíèå H3K9me3 P1 ïðîìîòîðíîé
îáëàñòè ãåíà TP53 êëåòî÷íîé ëèíèè MCF-7 ìîæåò áûòü ïðè÷è-
íîé áîëåå íèçêèõ óðîâíåé ýêñïðåññèè TP53, îïèñàííûõ ðàíåå íà-
øåé ãðóïïîé.
Êëþ÷åâûå ñëîâà: TP53, õðîìàòèí, ïåòëåâîé äîìåí, ÌÀÐ, ðàê
ìîëî÷íîé æåëåçû, ýïèãåíåòè÷åñêèå ìîäèôèêàöèè ãèñòîíîâ, ÷èï
àíàëèçà.
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